Radiopharmaceutical model using 9mTc-MIBI to evaluate amifostine protection against doxorubicin cardiotoxicity in rats

Annals of Nuclear Medicine

Volumn 19, Issue 3, 2005, Pages 197-200

  Yurekli, Yakup ^a   Unak, Perihan ^b   Ertay, Turkan ^c   Biber, Zumrut ^b   Medine, Ilker ^b   Teksoz, Scrap ^b  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

^b EGE UNIVERSITY   (Turkey)

^c DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

9mTc MIBI; Amifostine; Cardiotoxicity; Doxorubicin; Radiopharmaceutical

Indexed keywords

AMIFOSTINE; DOXORUBICIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; SODIUM CHLORIDE; ANTINEOPLASTIC AGENT; CARDIOTONIC AGENT; DIAGNOSTIC AGENT;

ANALYZER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CELL PROTECTION; CONTROLLED STUDY; DRUG UPTAKE; HEART MUSCLE; HEART PROTECTION; IN VIVO STUDY; MALE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; RADIOACTIVITY; RAT; ANIMAL; CARDIOMYOPATHY; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG INTERACTION; SCINTISCANNING; TREATMENT OUTCOME; WISTAR RAT;

AMIFOSTINE; ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; CYTOPROTECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG INTERACTIONS; MALE; MODELS, ANIMAL; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; TECHNETIUM TC 99M SESTAMIBI; TREATMENT OUTCOME;

EID: 21044459884     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02984605     Document Type: Article

References (26)

1. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1997; 54: 1-7.
2. Vasquez-Vivar J, Martasek P, Hogg N, Masters BS, Pritchard KA Jr, Kalyanaraman B. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochem 1997; 36: 11293-11297.
3. Rajagopalan S, Politi PM, Sinha BK, Myers CE. Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res 1988; 48: 4766-4769.
4. Dorr R. Chemoprotectants for cancer chemotherapy. Semin Oncol 1991; 18: 48-58.
5. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10: 117-127.
6. Myers C, Bonow R, Palmeri S, et al. A randomised controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol 1983; 10: 53-55.
7. Mahaney Jr FX. Agent designed for war now in doctor's armamentarium. J Natl Cancer Inst 1990; 82: 255-257.
8. Koukourakis MI. Amifostine in clinical oncology: current use and future applications. Anticancer Drugs 2002; 13: 181-209.
9. Santini V. Amifostine: chemotherapeutic and radiotherapeutic protective effects. Expert Opin Phamacother 2001; 2: 479-489.
10. Brizel DM, Overgaard J. Does amifostine have a role in chemoradiation treatment? Lancet Oncol 2003; 4: 378-381.
11. Sampson CB. Adverse reactions and drug interactions with radiopharmaceuticals. Drug Saf 1993; 8: 280-294.
12. Hesslewood S, Leung E. Drug interactions with radiopharmaceuticals. Eur J Nucl Med 1994; 21: 348-356.
13. Hladik WB, Nigg KK, Rhodes BA. Drug-induced changes in the biologic distribution of radiopharmaceuticals. Semin Nucl Med 1982; 7: 184-218.
14. Jain D. Technetium-99m labeled myocardial perfusion imaging agents. Semin Nucl Med 1999; 29: 221-236.
15. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis(2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. J Nucl Med 1990; 31: 1646-1653.
16. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis(2-methoxyisobutyl isonitrile)technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 1990; 82: 1826-1838.
17. Carvalho PA, Chiu ML, Kronauge JF, et al. Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J Nucl Med 1992; 33: 1516-1522.
18. Sampson CB. Adverse reactions and drug interactions with radiopharmaceuticals. Drug Saf 1993; 8: 280-294.
19. Venditti P, Balestrieri M, De Leo T, Di Meo S. Free radical involvement in doxorubicin-induced electrophysiological alterations in rat papillary muscle fibres. Cardiovasc Res 1998; 38: 695-702.
20. Fadillioglu E, Erdogan H. Effects of erdosteine treatment against doxorubicin-induced toxicity through erythrocyte and plasma oxidant/antioxidant status in rats. Pharmacol Res 2003; 47: 317-322.
21. 99mTc-DTPA in Balb/c mice. J Exp Clin Cancer Res 1998; 17: 313-316.
22. Gomes ML, de Mattos DM, de Souza Freitas R, Bezerra RJ, Bernardo-Filho M. Study of the toxicological effect of mitomycin C in mice: alteration on the biodistribution of radiopharmaceuticals used for renal evaluations. Hum Exp Toxicol 2001; 20: 1993-1997.
23. Mattos DM, Gomes ML, Freitas RS, et al. The effect of vincristine on the biodistribution of technetium-99m DTPA, GHR, and DMSA in Balb/c female mice. J Nucl Med Tech 2000; 28: 271-274.
24. Miyagawa M, Tanada S, Hamamoto K. Scintigraphic evaluation of myocardial uptake of thallium 201 and technetium 99m pyrophosphate utilizing a rat model of chronic doxorubicin cardiotoxicity. Eur J Nucl Med 1991; 18: 332-338.
25. Piwnica-Worms D, Chiu ML, Kronauge JF. Detection of adriamycin-induced cardiotoxicity in cultured heart cells with technetium 99m sestamibi. Cancer Chemother Pharmacol 1993; 32: 385-391.
26. Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology Clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17: 3333-3355.